Search
Products
Community
Markets
News
Brokers
More
IN
Get started
Community
/
Ideas
/
$IDXG On The Run Again and this time it will be sustained
Long
$IDXG On The Run Again and this time it will be sustained
By StockGuild
Follow
Follow
Updated
Mar 29, 2017
6
Mar 29, 2017
Let's recap
IDXG
CC:
1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG
European Patent Decision
data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP
ALSO FULL YEAR HIGHLIGHTS READ HERE:
ih.advfn.com/p.php?pid=nmona&article=74215692
Mar 29, 2017
Note
Alerted this on Twitter earlier in the day. Will post charts in real time next time.
BAC
breakout
Facebook (FB)
FNMA
Fundamental Analysis
IDXG
microcap
snap
technicals
TWTR
StockGuild
Follow
Also on:
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the
Terms of Use
.